Tuesday, February 28, 2023
Financial News Conference on the Full Year 2022 Results
Bayer: Significant Growth in Sales and Earnings
- Group sales increase 8.7 percent (Fx & portfolio adj.) to 50.739 billion euros
- EBITDA before special items rises 20.9 percent to 13.513 billion euros, largely driven by exceptionally strong performance at Crop Science
- Pharmaceuticals increases sales and earnings
- Consumer Health maintains dynamic growth
- Core earnings per share advance 22.0 percent to 7.94 euros
- Net income of 4.150 billion euros
- Free cash flow increases to 3.111 billion euros, net financial debt down to 31.809 billion euros
- Dividend of 2.40 euros per share proposed, up 20 percent
- New products post significant growth / Encouraging developments in the research pipeline
- Major progress made toward achieving long-term sustainability targets
- Outlook for 2023: Increase in sales (Fx & portfolio adj.); EBITDA before special items and core earnings per share below prior year as inflation remains high
